Thoracic malignancies are challenging diseases, with high heterogeneity in clinical, radiological, histopathological, and molecular features.
Most thoracic lesions are revealed as malignancies, potentially comprising any organ and so including tumors of the lung, pleura, and pericardium, heart, and mesenchymal tumors, tumors of the thymus, germ cell tumors, metastases, and many genetic syndromes involving the thorax.
Diagnosis is based on detailed imaging and histologic-immunohistochemical findings, that strictly provide information for the best treatment planning, such as surgery or systemic therapy leading to personalized approach and tailored therapies.
Traditional approaches include surgery, radiotherapy, and systemic therapy with many limitations, so safer and more effective methods are required.
In particular, the concept of “theragnostic” has been developed in recent years. Theragnostic is the combination of two approaches (diagnostic and therapeutic). With particular regard to nuclear medicine, this concept refers to radiopharmaceuticals containing radionuclides for diagnosis and therapy. In current clinical practice, several theragnostic pairs are widely used and include alpha and beta emitters.
Moreover, nanotechnology is currently available to diagnose and treat cancer in the field of nanomedicine with particular attention to Selenium nanoparticles, that provided good prospects with regards to lung cancer treatment.
This Research Topic aims to provide a comprehensive, multidisciplinary perspective on the role of theragnostic in thoracic malignancies, evaluating their impact on patients' health and outcomes. Specifically, we seek contributions that:
• Present the latest findings on theragnostic, especially in thoracic malignancies • Highlight the current role of theragnostic on patient management and outcome and future perspective • Integrate insights from various disciplines such as nuclear medicine, nuclear physics, thoracic surgery, radiotherapy, and oncology
We welcome diverse manuscript types, including empirical and review studies, and cohort studies. This collection aims to foster interdisciplinary collaboration and innovation in theragnostic research and clinical management of people affected by thoracic malignancies.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public omics databases that are not supplemented by relevant functional validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Article types and fees
This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:
Brief Research Report
Case Report
Clinical Trial
Editorial
FAIR² Data
FAIR² DATA Direct Submission
General Commentary
Hypothesis and Theory
Methods
Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.
Article types
This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:
Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
